Chronic Atrophic Gastritis Associated with Hyperparathyroidism: A prospective Study Abstract #263

Introduction: The association of gastric carcinoids (GCs) type 1 and hyperparathyroidism (HPTH) has been reported, whereas a possible association between chronic atrophic gastritis (CAG) and HPTH is still scant.
Aim(s): To prospectively evaluate the possible association between HPTH and CAG in both a series of CAG patients and a series of sporadic HPTH patients.
Materials and methods: From 1999 to 2010, two series of patients were studied: 99 consecutive hystologically confirmed CAG (81 female, aged 20-88 yrs), with (19) or without GCs (80) and 149 consecutive patients with HPTH (119 female, aged 35-87 yrs). All patients underwent laboratory tests and CAG and hypergastrinemic HPTH underwent upper gastrointestinal endoscopy.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Sara Massironi

To read results and conclusion, please login ...

Further abstracts you may be interested in

#295 Unusual Behavior of Gastric Carcinoid Type 1
Introduction: Gastric carcinoids (GC) are rare tumors of the stomach. GC type 1 are associated with chronic atrophic gastritis (CAG) and are the most benign type, having low metastatic potential.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Matilde P Spampatti
#621 Occurrence of Type 1 Gastric Carcinoid In Patients with Autoimmune Chronic Atrophic Gastritis
Introduction: The actual incidence of type1 gastric carcinoids (GC1) as a long-term complication of chronic autoimmune atrophic gastritis (CAAG) remains to be clarified as studies are few.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Dr Roberta E Rossi
#818 Treatment with Somatostatin Analogs of Recurrent Type I Gastric Carcinoid in Patients with Autoimmune Chronic Atrophic Gastritis
Introduction: The treatment of type 1 gastric carcinoids (GC1) is still debated, in view of their usual benign behavior.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: PhD Sara Massironi
#2804 Claudin-18 Is a Sensitive and a Specific Marker for Gastric Neuroendocrine Tumors
Introduction: Antibody-based cancer therapies are emerging as promising therapeutics in oncology, including one in clinical trials that targets claudin-18, a protein expressed in normal gastric epithelium and some gastric adenocarcinoma. We currently have no markers for gastric well-differentiated neuroendocrine tumors (NETs).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Pathology - grading, staging
Presenting Author: Housestaff Mary Wong
Authors: Wong M, Huynh C, Kim S, Dhall D, ...
#11 Plasma chromogranin - A response to octreotide test: Prognostic value for clinical outcome in endocrine digestive tumors
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) expressing somatostatin receptors may be treated with somatostatin analogues (SSAs). Selection criteria are a positive Octreoscan® or a >50% hormone level decrease after octreotide s.c. injection (octreotide test) (OT). Plasma chromogranin A (CgA) is the best general GEP-NET marker, but data on CgA response to OT are scant.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD, PhD Sara Massironi